A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners

Journal of Substance Abuse Treatment

Volumn 59, Issue , 2015, Pages 52-58

  Gordon, Michael S ^a,b   Kinlock, Timothy W ^a,c   Vocci, Frank J ^a   Fitzgerald, Terrence T ^d   Memisoglu, Asli ^e   Silverman, Bernard ^e  

^a FRIENDS RESEARCH INSTITUTE   (United States)

^b STEVENSON UNIVERSITY   (United States)

^c UNIVERSITY OF BALTIMORE   (United States)

^d Glenwood Life Counseling Center   (United States)

^e Alkermes Inc   (Ireland)

Author keywords

Heroin addiction; Long acting naltrexone; Prisoners

Indexed keywords

COCAINE; NALTREXONE; OPIATE; DELAYED RELEASE FORMULATION; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; COCAINE DEPENDENCE; COMMUNITY; DRUG FORMULATION; DRUG SCREENING; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; INJECTION; MALE; MEDICAL HISTORY; OFFENDER; OPEN STUDY; OPIATE ADDICTION; PHASE 4 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PRISON; PRISONER; RECIDIVISM; URINALYSIS; DELAYED RELEASE FORMULATION; MIDDLE AGED; OPIOID-RELATED DISORDERS; TREATMENT OUTCOME;

ADULT; DELAYED-ACTION PREPARATIONS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PILOT PROJECTS; PRISONERS; TREATMENT OUTCOME;

EID: 84944871936     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2015.07.005     Document Type: Article

References (51)

1. Binswanger I.A., Nowels C., Corsi K.F., Long J., Booth R.E., Kutner J., et al. From the prison door right to the sidewalk, everything went downhill. A qualitative study of the health experiences of recently released inmates. International Journal of Law and Psychiatry 2011, 34(4):249-255.
2. Binswanger I.A., Stern M.F., Deyo R.A., Heagerty P.J., Cheadle A., Elmore J.G., et al. Release from prison-A high risk of death for former inmates. New England Journal of Medicine 2007, 356(2):157-165.
3. Bird S.M., Hutchinson S.J. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-99. Addiction 2003, 98(2):185-190.
4. Brownstein H.H. Contemporary Drug Policy 2013, Routeledge, New York.
5. Carson E.A., Golinelli D. Prisoners in 2012: Advance counts 2013, Department of Justice, Bureau of Justice Statistics, Washington, D.C.
6. Chandler R.K., Fletcher B.W., Volkow N.D. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA 2009, 301(2):183-190.
7. Coviello D.M., Cornish J.W., Lynch K.G., Boney T.Y., Clark C.A., Lee J.D., et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Substance Abuse 2012, 33(1):48-59. (PMCID: PMC3365863).
8. Di Paola A., Lincoln T., Skiest D.K., Desabrais M., Altice F.L., Springer S. Design and methods of a double blind randomized placebo-controlled trial of extened-release naltrexone for HIV-infected opioid dependent prisoners and jail detainees who are transitioning to community. Contemporary Clinical Trials 2014, 39(2):256-268.
9. Dolan K., Khoei E.M., Brentari C., Stevens A. Prison and drugs: A global review of incarceration, drug use, and drug services 2007, The Beckley Foundation, Drug Policy Programme.
10. Dolan K.A., Shearer J., MacDonald M., Mattick R.P., Hall W., Wodak A.D. A randomized controlled trial of methadone maintenance treatment versus wait list control in an Australian Prison System. Drug and Alcohol Dependence 2003, 72:59-65.
11. Dole V.P., Robinson J.W., Orraca J., Towns E., Searcy P., Caine E. Methadone treatment of randomly selected criminal addicts. New England Journal of Medicine 1969, 280(25):1372-1375.
12. Farrell M., Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction 2008, 103(2):251-255.
13. Fazel S., Bains P., Doll H. Substance abuse and dependence in prisoners: A systematic review. Addiction 2006, 101(2):181-191.
14. Friedmann P.D., Hoskinson R., Gordon M., Schwartz R., Kinlock T., Knight, et al. Medication-Assisted treatment in the criminal justice drug abuse treatment studies (CJ-DATS 2): Availability, need, barriers and readiness. Substance Abuse 2012, 33(1):9-18.
15. Gastfriend D.R., Dong Q., Loewy J., Silverman B., Ehrich E. Durability of effect of long-acting injectable naltrexone. American Psychiatric Association Institute 2005.
16. Gordon M.S., Kinlock T.W., Schwartz R.P. A randomized clinical trial of methadone maintenance for prisoners: Findings at 12-months post release. Presented as part of a symposium: Incarceration and opioid dependence: Impact, interventions, and implications. Addiction Health Services Research Conference. Boston, MA 2008.
17. Gordon M.S., Kinlock T.W., Schwartz R.P., Fitzgerald T.T., O'Grady K.E., Vocci F.J. A randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entry. Drug and Alcohol Dependence, Sep. 1 2014, 142:33-40.
18. Gordon M.S., Kinlock T.W., Schwartz R.P., Couvillion K.A., Sudec L.J., O'Grady K.E., et al. Buprenorphine treatment for probationers and parolees. Substance Abuse 2015, 36(2):217-225.
19. Hedrich D., Alves P., Farrell M., Stoveer H., Moller L., Mayet S. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction 2012, 107(3):501-517.
20. Hough M. Drug user treatment within a criminal justice context. Substance Use and Misuse 2002, 37(8-10):985-996.
21. Inciardi J. The war on drugs IV 2008, Prentice Hall, Upper Saddle River, NJ. 4th ed.
22. Kanato M. Drug use and health among prison inmates. Current Opinion in Psychiatry 2008, 21(3):252-254.
23. Kastelic A., Pont J., Stöver H. Opioid substitution treatment in custodial settings. A practical guide 2008, BIS-Verlag, Oldenburg.
24. Kinlock T.W., Gordon M.S., Schwartz R.P. Incarcerated populations. Lowinson & Ruiz's substance abuse: A comprehensive textbook 2011, Lippincott Williams & Wilkins. 5th ed. P. Ruiz, E. Strain (Eds.).
25. Kinlock T.W., Gordon M.S., Schwartz R.P., Fitzgerald T.T., O'Grady K.E. A randomized clinical trial of methadone maintenance for prisoners: Results at 12 months post-release. Journal of Substance Abuse Treatment 2009, 37(3):277-285. (PMCID: PMC2803487).
26. Kinlock T.W., Gordon M.S., Schwartz R.P., O'Grady K.E. A Study of methadone maintenance for male prisoners: 3-Month post-release outcomes. Criminal Justice Behavior 2008, 35(1):34-47. (PMCID: PMC2443939).
27. Kinlock T.W., Gordon M.S., Schwartz R.P., O'Grady K., Fitzgerald T.T., Wilson M. A randomized clinical trial of methadone maintenance for prisoners: Results at 1-month post-release. Drug and Alcohol Dependence 2007, 91(2-3):220-227. (PMCID: PMC2423344).
28. Kinlock T.W., Gordon M.S., Shabazz H. Pharmacotherapy for incarcerated individuals with histories of heroin addiction. Heroin addiction: Prevalence, treatment approaches and health consequences 2015, 127-142. Nova Science Publishers, Inc., Hauppauge, NY. A.M. Fareed (Ed.).
29. Kinlock T.W., O'Grady K.E., Hanlon T.E. Prediction of the criminal activity of incarcerated drug-abusing offenders. Journal of Drug Issues 2003, 33:897-920.
30. Krinsky C.S., Lathrop S.L., Brown P., Nolte K.B. Drugs, detention, and death: A study of the mortality of recently released prisoners. American Journal of Forensic Medicine and Pathology 2009, 30(1):6-9.
31. Krupitsky E., Zvartau E., Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Current psychiatry reports 2010, 12(5):448-453.
32. Latkin C.A., Yang C., Tobin K.E., German D. Injection drug users' and their risk networks' experiences of and attitudes towards drug dealer violence in Baltimore, Maryland. International Journal of Drug Policy 2013, 24(2):135-141.
33. Lee J.D., McDonald R., Grossman E., McNeely J., Laska E., Rotrosen J., et al. Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial. Addiction 2015, ([Epub ahead of print] PubMed PMID: 25703440). 10.1111/add.12894.
34. Lee J.D., Friedmann P.D., Boney T.Y., Hoskinson R.A., McDonald R., Gordon M., et al. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial. Contemporary Clinical Trials 2015, 41:110-117.
35. Lee J., Friedman P., McDonald R., Gordon M., Nunes E., Hoskinson R., et al. Extended-release naltrexone for opioid relapse prevention among community CJS participants 2015, Podium, CPDD, Phoenix, AZ.
36. Magura S., Lee J.D., Hershberger J., Joseph H., Marsch L., Shropshire C., et al. Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial. Drug and Alcohol Dependence 2009, 99(1-3):222-230.
37. Magura S., Rosenblum A., Lewis C., Joseph H. The effectiveness of in-jail methadone maintenance. Journal of Drug Issues 1993, 23:75-99.
38. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat 1992, 9(3):199-213.
39. Merrall E.L., Kariminia A., Binswanger I.A., Hobbs M.S., Farrell M., Marsden J., et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction 2010, 105(9):1545-1554.
40. Metz V., Matzenauer C., Kammerer K., Winklbaur B., Ebner N., Radler D., et al. Evaluation of opioid-dependent prisoners in oral opioid maintenance therapy. Heroin Addiction and Related Clinical Problems 2010, 12(1):5-16.
41. Mumola C.J., Karberg J.C. Drug use and dependence, state and federal prisoners, 2004 2006, U.S. Department of Justice, Bureau of Justice Statistics, Washington, D.C, (NCJ 213530).
42. Nunn A., Zaller N., Dickman S., Trimbur C., Nijhawan A., Rich J.D. Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey. Drug and Alcohol Dependence 2009, 105:83-88.
43. Nurco D.N., Hanlon T.E., Kinlock T.W. Recent research on the relationship between illicit drug use and crime. Behavioral Sciences and the Law 1991, 9:221-241.
44. Rich J.D., Boutwell A.E., Shield D.C., Key R.G., McKenzie M., Clarke J.G., et al. Attitudes and practices regarding the use of methadone in US state and federal prisons. Journal of Urban Health 2005, 82(3):411-419.
45. Stewart L.M., Henderson C.J., Hobbs M.S., Ridout S.C., Knuiman M.W. Risk of death in prisoners after release from jail. Australian and New Zealand Journal of Public Health 2004, 28(1):32-36.
46. Stover H., Michels I.I. Drug use and opioid substitution treatment for prisoners. Harm Reduction Journal 2010, 7:17.
47. Strang J., Gossop M., Heuston J., Green J., Whiteley C., Maden A. Persistence of drug use during imprisonment: Relationship of drug type, recency of use and severity of dependence to use of heroin, cocaine and amphetamine in prison. Addiction 2006, 101(8):1125-1132.
48. Taxman F.S., Perdoni M., Harrison L.D. Drug treatment services for adult offenders: The state of the state. Journal of Substance Abuse Treatment 2007, 32:239-254.
49. Tomasino V., Swanson A.J., Nolan J., Shuman M. The Key Extended Entry Program (KEEP): A methadone treatment program for opiate-dependent inmates. The Mount Sinai Journal of Medicine 2001, 68:14-20.
50. Wish E.D., Artigiani E., Billing A., et al. The emerging buprenorphine epidemic in the United States. Journal of addictive diseases 2012, 31(1):3-7.
51. Zaller N., McKenzie M., Friedman P.D., Green T.C., McGowan S., Rich J.D. Initiation of buprenorphine during incarceration and retention in treatment upon release. Journal of Substance Abuse Treatment 2013, 45(2):222-226.